The KDM2B Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung adenocarcinoma epithelial cell line. This heterogeneous pool harbors disruptions in the KDM2B gene, creating a loss-of-function model that does not rely on clonal isolation. The polyclonal format captures the genetic variability of tumor cell populations, enabling studies of diverse cellular responses to KDM2B ablation.
A-549 cells serve as a widely used model for human lung adenocarcinoma, characterized by an adherent epithelial morphology and a KRAS G12S mutation. Originally derived from type II alveolar epithelial cells, this line is employed in cancer biology and drug discovery to investigate oncogenic mechanisms, drug responses, and epithelial cell behavior. Its genetic background provides a relevant context for exploring the role of chromatin modifiers in lung cancer.
KDM2B functions as a histone demethylase that specifically targets H3K4me3 and H3K36me2, leading to transcriptional repression of downstream targets such as CDKN1A (p21) and CDKN2A (p16). It also acts as an F-box protein within a non-canonical Polycomb repressive complex 1 (PRC1), interacting with RING1/RNF2, BMI1, and CBX proteins to facilitate ubiquitination-mediated gene silencing. Upstream regulators include TGF-??/SMAD effectors like TGFB1, TGFBR1/2, and SMAD2/3/4, as well as TP53 and MYC. KDM2B further intersects with the Wnt/??-catenin pathway through components including WNT3A, FZD, CTNNB1, and TCF/LEF transcription factors, thereby linking extracellular signals to chromatin state and the control of cell cycle progression, apoptosis, and senescence.
In the A-549 lung adenocarcinoma model, KDM2B knockout allows dissection of its context-dependent roles as both a potential tumor suppressor and oncogene, particularly in conjunction with KRAS-driven signaling. The polyclonal knockout population enables observation of variable phenotypic outcomes??such as altered proliferation rates, apoptosis induction, and epigenetic reprogramming??reflecting the heterogeneity of therapeutic responses in lung tumors. This system is valuable for examining cross-talk between TGF-?? and Wnt pathways and chromatin regulation.
Researchers can apply these cells in functional genomics studies to map KDM2B-dependent gene expression changes via RNA-seq and to assess histone modification dynamics by ChIP-qPCR. The model supports drug sensitivity assays for epigenetic therapeutics, co-immunoprecipitation of PRC1 components, and flow cytometric analysis of cell cycle and apoptosis. Migration and invasion assays may be used to explore metastatic traits. For further details, please contact Ascent Research.
